{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Yin H"],"funding":["Science and Technology Commission of Shanghai Municipality","Shanghai Municipal Hospital Development Center","Fujian Provincial Department of Science and Technology"],"pagination":["2"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12715071"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["75(1)"],"pubmed_abstract":["<h4>Background</h4>Current understanding of neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC) lacks high-level evidence. This study provides additional efficacy data for this treatment regimen.<h4>Methods</h4>Clinical trials investigating neoadjuvant tislelizumab plus chemotherapy in locally advanced ESCC were identified through literature search. Raw data from investigators were pooled for analysis. Primary endpoint was pCR; secondary endpoints included MPR, R0 resection rate, EFS, DFS, and OS.<h4>Results</h4>Six studies involving 306 patients were analyzed; 275 (89.9%) underwent surgery. Among surgical patients, pCR rate was 25.5% and MPR rate was 49.5%. Most patients (98.5%) achieved R0 resection. At median follow-up of 31.3 months, median EFS"],"journal":["Cancer immunology, immunotherapy : CII"],"pubmed_title":["Long-term outcome of neoadjuvant tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma."],"pmcid":["PMC12715071"],"funding_grant_id":["SHDC2020CR4039","2021D014","20ZR1411600"],"pubmed_authors":["Li G","Tan L","Liao X","Wang J","Sun Y","Yan X","Duan H","Yang X","Yin H","Liang F","Fan H","Wang P","Chen Y","Yao G"],"additional_accession":[]},"is_claimable":false,"name":"Long-term outcome of neoadjuvant tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.","description":"<h4>Background</h4>Current understanding of neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma (ESCC) lacks high-level evidence. This study provides additional efficacy data for this treatment regimen.<h4>Methods</h4>Clinical trials investigating neoadjuvant tislelizumab plus chemotherapy in locally advanced ESCC were identified through literature search. Raw data from investigators were pooled for analysis. Primary endpoint was pCR; secondary endpoints included MPR, R0 resection rate, EFS, DFS, and OS.<h4>Results</h4>Six studies involving 306 patients were analyzed; 275 (89.9%) underwent surgery. Among surgical patients, pCR rate was 25.5% and MPR rate was 49.5%. Most patients (98.5%) achieved R0 resection. At median follow-up of 31.3 months, median EFS","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Dec","modification":"2026-06-06T04:59:38.612Z","creation":"2026-05-26T03:12:14.53Z"},"accession":"S-EPMC12715071","cross_references":{"pubmed":["41410741"],"doi":["10.1007/s00262-025-04240-8"]}}